Insulin suppresses endothelial secretion of C-type natriuretic peptide, a novel endothelium-derived relaxing peptide

被引:30
作者
Igaki, T [1 ]
Itoh, H [1 ]
Suga, S [1 ]
Komatsu, Y [1 ]
Ogawa, Y [1 ]
Doi, K [1 ]
Yoshimasa, T [1 ]
Nakao, K [1 ]
机构
[1] KYOTO UNIV, GRAD SCH MED, DEPT MED & CLIN SCI, SAKYO KU, KYOTO 606, JAPAN
关键词
D O I
10.2337/diab.45.3.S62
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We have previously reported that C-type natriuretic peptide (CNP), the third member of the natriuretic peptide family, is produced in vascular endothelial cells (ECs) and acts as an endothelium-derived relaxing peptide, Ne further demonstrated the detection of the gene transcripts of CNP and atrial natriuretic peptide (ANP) B receptor, a specific receptor for CNP, in human blood vessels, Ne thus propose the existence of a vascular natriuretic peptide system (NPS), CNP secretion mas also demonstrated to be stimulated by various growth factors and cytokines, To clarify the significance of vascular NPS in proliferative vascular complications associated with diabetes, hypertension, or atherosclerosis, in the present study we examined the effect of insulin on CNP secretion from cultured ECs, Insulin at a concentration in the physiological range (10(-10)-10(-7) mol/l) potently suppressed CNP secretion, whereas insulin at the same concentration did not suppress endothelin (ET) secretion from EC, IGF-I had no significant effect on CNP secretion. Insulin, therefore, can be a potent inhibitor of CNP secretion through the activation of insulin receptor, Since CNP has been shown to be a potent inhibitor of vascular smooth muscle cell proliferation, the present study suggests the possibility that attenuated activity of vascular NPS is associated with hyperinsulinemia, which might result in proliferative vascular lesions.
引用
收藏
页码:S62 / S64
页数:3
相关论文
共 26 条
[1]   INSULIN, INSULIN-LIKE GROWTH FACTOR-I AND PLATELET-DERIVED GROWTH-FACTOR INTERACT ADDITIVELY IN THE INDUCTION OF THE PROTOONCOGENE C-MYC AND CELLULAR PROLIFERATION IN CULTURED BOVINE AORTIC SMOOTH-MUSCLE CELLS [J].
BANSKOTA, NK ;
TAUB, R ;
ZELLNER, K ;
KING, GL .
MOLECULAR ENDOCRINOLOGY, 1989, 3 (08) :1183-1190
[2]   HYPERTENSION, INSULIN, AND ATHEROGENESIS [J].
CONNELL, JMC .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1991, 18 :S45-S50
[3]   ATRIAL NATRIURETIC FACTOR - A HORMONE PRODUCED BY THE HEART [J].
DEBOLD, AJ .
SCIENCE, 1985, 230 (4727) :767-770
[4]   INSULIN RESISTANCE - A MULTIFACETED SYNDROME RESPONSIBLE FOR NIDDM, OBESITY, HYPERTENSION, DYSLIPIDEMIA, AND ATHEROSCLEROTIC CARDIOVASCULAR-DISEASE [J].
DEFRONZO, RA ;
FERRANNINI, E .
DIABETES CARE, 1991, 14 (03) :173-194
[5]   INSULIN RESISTANCE IN ESSENTIAL-HYPERTENSION [J].
FERRANNINI, E ;
BUZZIGOLI, G ;
BONADONNA, R ;
GIORICO, MA ;
OLEGGINI, M ;
GRAZIADEI, L ;
PEDRINELLI, R ;
BRANDI, L ;
BEVILACQUA, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (06) :350-357
[6]   C-TYPE NATRIURETIC PEPTIDE IS A GROWTH INHIBITOR OF RAT VASCULAR SMOOTH-MUSCLE CELLS [J].
FURUYA, M ;
YOSHIDA, M ;
HAYASHI, Y ;
OHNUMA, N ;
MINAMINO, N ;
KANGAWA, K ;
MATSUO, H .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 177 (03) :927-931
[7]   DETECTION OF C-TYPE NATRIURETIC PEPTIDE IN HUMAN CIRCULATION AND MARKED INCREASE OF PLASMA CNP LEVEL IN SEPTIC SHOCK PATIENTS [J].
HAMA, N ;
ITOH, H ;
SHIRAKAMI, G ;
SUGA, S ;
KOMATSU, Y ;
YOSHIMASA, T ;
TANAKA, I ;
MORI, K ;
NAKAO, K .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1994, 198 (03) :1177-1182
[8]  
Itoh H, 1994, Blood Press Suppl, V5, P49
[9]   ATRIAL NATRIURETIC POLYPEPTIDE INHIBITS HYPERTROPHY OF VASCULAR SMOOTH-MUSCLE CELLS [J].
ITOH, H ;
PRATT, RE ;
DZAU, VJ .
JOURNAL OF CLINICAL INVESTIGATION, 1990, 86 (05) :1690-1697
[10]   PURIFICATION AND COMPLETE AMINO-ACID-SEQUENCE OF ALPHA-HUMAN ATRIAL NATRIURETIC POLYPEPTIDE (ALPHA-HANP) [J].
KANGAWA, K ;
MATSUO, H .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1984, 118 (01) :131-139